# Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides

> **NCT01645293** · PHASE1 · UNKNOWN · sponsor: **University of Cologne** · enrollment: 15 (estimated)

## Conditions studied

- CD30 Positive Cutaneous T Cell Lymphoma
- CD30 Positive Transformed Mycosis Fungoides

## Interventions

- **GENETIC:** Genetically modified T cells # 1138

## Key facts

- **NCT ID:** NCT01645293
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2012-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01645293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01645293, "Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01645293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*